Sosei Co., Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sosei Co., Ltd
Japan has granted an emergency approval to Chugai/Roche/Regeneron's antibody cocktail after a rapid review, while India has emerged as one of the top purchasers globally of COVID-19 vaccines as it looks to protect more of its population.
Deal Snapshot: Following its diabetes deal with Biolojic by four months, Lilly’s partnership with Verge on using AI to discover ALS drugs is just the latest of numerous tech-biopharma tie-ups.
Sosei Heptares hopes to create transformative therapeutics for immune diseases by combining its GPCR structure-based drug design and early development capabilities with InveniAI's already validated AI-based platform, its head of new target identification tells Scrip.
Competition to bring new schizophrenia therapies to market is increasing, with the need to demonstrate side-effect improvements over existing drugs especially important.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Heptares Therapeutics Limited
- Heptares Zurich
- G7 Therapeutics
- Sosei Heptares